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Paraneoplastic neurological syndromes (PNSs) occur in patients with cancer and can cause clinical symptoms and signs of
dysfunctionofthenervoussystemthatarenotduetoalocaleffectofthetumororitsmetastases.Mostoftheseclinicalsyndromesin
adults are associated with lung cancer, especially small cell lung cancer (SCLC), lymphoma, and gynecological tumors. The finding
ofhighlyspecificantibodiesdirectedagainstonconeuralantigenshasrevolutionizedthediagnosisandpromotedtheunderstanding
of these syndromes and led to the current hypothesis of an autoimmune pathophysiology. Accumulating data strongly suggested
direct pathogenicity of these antibodies. The field of PNS has expanded rapidly in the past few years with the discovery of limbic
encephalitis associated with glutamic acid decarboxylase (GAD) 65, the voltage (VGKC-gated potassium channel) complex, the
methyl(N-NMDA-D-aspartate),alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionicacid(AMPA),andgammaaminobutyric
acid(GABA)(B)receptors,andsoforth.Despitethis,theclinicalspectrumofthesediseaseshasnotyetbeenfullyinvestigated.The
clinical importance of these conditions lies in their frequent response to immunotherapies and, less commonly, their association
with distinctive tumors. This review provides an overview on the pathogenesis and diagnosis of PNS, with emphasis on the role of
antibodies in limbic encephalitis.
1. An Overview of Paraneoplastic
Neurological Syndromes
The idea that neural cells can be the target of autoimmune
r e s p o n s e sm e d i a t e db ya n t i b o d i e si ss t i l ln o tw e l lr e c o g n i z e d
in the medical community [1]. Paraneoplastic neurological
syndromes (PNSs) are rare dysfunctions of the nervous sys-
tem in patients with cancer, which are not due to a local
e ff e c to ft h et u m o ro ri t sm e t a s t a s e s .M o s to ft h e s ec l i n i c a l l y
defined syndromes in adults are associated with lung cancer,
especiallysmallcelllungcancer(SCLC),lymphoma,orgyne-
cological tumors. Antibodies directed against onconeural
antigens are frequently detected in patients with PNS. So far,
these antibodies have been thought to be the only markers
o ft h ed i s e a s ea n dn o tt op l a yar o l ei nt h ep a t h o p h y s i o l o -
gy. However, the recent description of antibodies directed
against membrane receptors or ion channels and playing a
pathogenic role has challenged this concept. In case of anti-
bodies targeting intracellular onconeural antigens, patients
almost always harbor a tumor; some tumors might be found
several years after the onset of neurological symptoms.
However, it is not the case in the patients with antibodies tar-
geting surface antigens (ion channels, receptors, or receptor
associated proteins).
The reported incidence of PNS varies greatly since most
estimates are from referral centers and not from population-
basedstudies[2].Paraneoplasticsensoryneuropathyisprob-
ably the most common (3–7 per 1000 cancer diagnoses),2 Mediators of Inflammation
followed closely by paraneoplastic encephalitis (3 per 1000)
and cerebellar degeneration (2 per 1000) [3]. A rough classi-
fication of PNS is illustrated in Table 1 [4].
2. Limbic Encephalitis: An Increasingly
Recognized Entity Belonging to PNS
The limbic system of brain comprises hippocampus, amyg-
dala, hypothalamus, corpus mamillare, fornix, and gyrus
cinguli (the Papez circuit) and is responsible for cognition,
affect, and autonomic regulation. Limbic encephalitis was
described for the first time by Brierley and colleagues in 1960
[5].Itischaracterizedbysubacuteonset(fromdaystoseveral
months)ofshort-termmemoryloss,disorientation,seizures,
confusion, behavioral disturbance, psychiatric symptoms,
and altered consciousness suggestive of involvement of the
limbic system [6]. Less frequently, patients can have delu-
sional thoughts and paranoid ideation [7], and some patients
may have hyponatremia.
In the last decades, limbic encephalitis has been exten-
sively investigated. According to the current knowledge, all
types of limbic encephalitis fall into one of two main cat-
egories, infectious or autoimmune etiology. Infectious lim-
b i ce n c e p h a l i t i si sc a u s e db yd i r e c ti n v a s i o no ft h eb r a i n
by infectious agents, usually viruses, whereas autoimmune
limbic encephalitis is caused by the individual’s autoimmune
reaction against itself. The current review will center on
autoimmune limbic encephalitis and its clinical character-
istics. Of note is that although the etiology was historically
considered paraneoplastic, limbic encephalitis may also arise
from nonparaneoplastic mechanisms, that is, autoimmune
processes independent of malignancy. The clinical presen-
t a t i o n sa r eq u i t es i m i l a ri nt h et w og r o u p s .P r o d r o m a lfl u -
like symptoms may point to a nonparaneoplastic etiology,
whereas smoking and weight loss suggest a paraneoplastic
etiology[8].Thedifficultyindifferentiatingthetwocategories
stems from the fact that in 60% to 70% of paraneoplastic
cases, neurological symptoms precede the detection of the
tumor [9, 10].
Established diagnosis of this syndrome after exclusion of
infective and toxic disorders should prompt the initiation
of immunotherapy [11]. The following investigations may
aid an accurate diagnosis: analysis of cerebrospinal fluid
(CSF), electroencephalogram (EEG), magnetic resonance
imaging (MRI), positron emission tomography (PET), and
detection of onconeural antibodies in the CSF and/or serum.
CSF usually shows lymphocytic pleocytosis, increased pro-
tein concentration, and oligoclonal bands. Regardless of the
typeofclinicalpresentation,EEGisalmostalwaysabnormal,
typically revealing focal or generalized slow wave abnor-
malities or epileptic form discharges in the temporal lobes
[12]; T2-weighted or fluid-attenuated inversion recovery
(FLAIR) MRI may show hyperintense signals of the medial
temporal lobes, although other sites of lesions can also be
detected (Figure 1);
18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) may detect hypermetabolism in
the medial temporal lobes, even when MRI is normal [12];
various antibodies may be present in serum and CSF. The
information provided by the combination of clinical, EEG,
Figure1:MRIFLAIRofapatientwithlimbicencephalitisandposi-
tiveNMDARantibodiesintheCSF.Increasedsignalintensityisseen
in the bilateral medial temporal lobes and hippocampi.
MRI,andCSFroutinestudiessuggeststhediagnosisoflimbic
encephalitis in most patients with a classic presentation of
t h es y n d r o m e[ 12]. It is not mandatory that all investigations
show pathological features, and not all cases of limbic
encephalitis have typical MRI findings. However, if EEG,
MRI,andCSFanalysesareallnormal,thediagnosisoflimbic
encephalitis is highly unlikely [8]. The diagnostic criteria
for limbic encephalitis are listed in Table 2 [13], and the
differential diagnoses of limbic encephalitis are summarized
in Table 3.
Clinical characteristics of the different types of limbic
encephalitis significantly vary according to the antibody
type. NMDAR encephalitis often presents with cognitive
and behavioralabnormalities.Because psychiatric symptoms
are early and prominent, it is not rare for patients to be
treatedwithantipsychoticdrugsatonset.Subsequently,char-
acteristic features develop, including movement disorders
(orofacial dyskinesia, dystonia), seizures, speech disorder,
autonomic dysfunction, central hypoventilation, catatonia,
and depressed level of consciousness [8, 11]. Patients with
PNS and LGI1-antibodies usually present with classic limbic
encephalitis but may show some specific features, such as
hyponatremia, rapid eye movement (REM), sleep behavioral
disorders, or characteristic tonic seizures. Factually, the
concept that limbic encephalitis is an inflammatory disorder
strictly limited to anatomic regions of the limbic system is
inaccurate. In this regard, these nonrestricted inflammatory
boundariesaretheruleratherthantheexception,particularly
when the limbic encephalitis is paraneoplastic. This is evi-
denced by many pathologic studies that have shown inflam-
matory infiltration distant from the limbic system. In these
patients, a careful clinical evaluation almost always reveals
s i g n so fi n v o l v e m e n to fo t h e ra r e a so ft h en e r v o u ss y s t e m
t h a tm a yr e m a i nm i l do rb e c o m em o r ep r o m i n e n tt h a n
the symptoms of limbic dysfunction. For example, PNS inMediators of Inflammation 3
Table 1: Classification of paraneoplastic neurological syndromes.
Central nervous system
Limbic encephalitis
Encephalomyelitis
Brainstem encephalitis
Stiff-person syndrome
Opsoclonus-myoclonus
Subacute cerebellar degeneration
Paraneoplastic visual syndromes
Cancer-associated retinopathy
Melanoma-associated retinopathy
Paraneoplastic optic neuropathy
Motor neuron syndromes
Subacute motor neuronopathy
Other motor neuron syndromes
Peripheral nervous system
Acute sensorimotor neuropathy
Subacute sensory neuronopathy
Chronic sensorimotor neuropathy
Subacute autonomic neuropathy
Paraneoplastic peripheral nerve vasculitis
Neuromuscular junction and muscle
Myasthenia gravis
Lambert-Eaton syndrome
Polymyositis/dermatomyositis
Acute necrotizing myopathy
Cachectic myopathy
Neuromyotonia
many patients with anti-Hu antibodies may start as limbic
encephalitis that often evolves to encephalomyelitis with
dorsal root ganglionitis.
3. Tumors That Are Associated with
Limbic Encephalitis
In PNS, 50% to 80% of the patients present with neuro-
logical symptoms of PNS prior to diagnosis of tumors [15].
The associated tumors in PNS are a lung cancer in 50–
60% of patients, usually SCLC (40–55%), and the associ-
ated tumor is a testicular germ cell tumor in 20% of patients.
Other associated tumors include breast cancer, thymoma,
Hodgkin’s lymphoma, and teratomas [2]. In paraneoplastic
limbic encephalitis, the most common tumors and corre-
sponding antibodies are SCLC (anti-Hu, anti-CRMP5, and
anti-amphiphysin), testicular cancer (anti-Ma2), thymoma
(anti-CRMP5),andbreastcancer(anti-amphiphysin)[16].In
menyoungerthantheageof50yearswithanti-Ma2antibod-
ies, limbic encephalitis is almost always associated with tes-
ticular germ cell tumors, which however can be microscopic
and difficult to detect.
As one of the classical PNS, limbic encephalitis can be
diagnosed within less than 5 years before cancer is detected
[14].Removalofthetumoriscriticalforneurologicimprove-
ment or stabilization of symptoms in PNS. Therefore, tumor
should be screened in patients with limbic encephalitis.
4. Antibodies Commonly Detected in
Limbic Encephalitis
Tumor immunologists introduced the term “onconeural”
antibodiestodesignateantibodiesthattargetantigenspresent
in neuroectodermal tissues and tumors [17]. These antibod-
ies are unambiguously demonstrated by standardized tests,
associated with limited subsets of tumors, and are present
in several PNS types [1]. Since the 1980s, various onconeural
antibodieshavebeendiscovered,whichcanserveasbiomark-
ersforclassicparaneoplasticsyndromes[18].Classicallimbic
encephalitides with temporal lobe seizures are associated
with onconeural antibodies directed against the intracellular
antigens. Onconeural antibodies are found in about 60%
of the patients with paraneoplastic limbic encephalitis. The
most frequent related antibodies are anti-Hu, anti-Ma2 (with
or without Ma1), anti-amphiphysin, and anti-CRMP5. The
majority of patients with anti-Hu antibodies have symptoms
also suggestive of the dysfunction of areas of the nervous
system outside the limbic system.
In recent years, the spectrum of chronic inflammatory
b r a i nd i s e a s e sc h a r a c t e r i z e db yt h ep r e s e n c eo fa n t i g e n -
specific antibodies in serum and CSF has greatly expanded.
Many patients with paraneoplastic limbic encephalitis pre-
viously characterized as “seronegative” have in fact anti-
bodies against cell surface antigens. Recent studies indi-
cated that most cases previously considered “seronega-
tive” have, in fact, antibodies against surface antigens [19].
More and more cases such as glutamic acid decarboxylase
(GAD) 65 antibody encephalitis [20], the voltage-gated
potassium channel (VGKC) complex antibody encephalitis
[21] (including LGI1 and Caspr2 antibodies), N-methyl-D-
aspartate receptor (NMDAR) antibody encephalitis [22],
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionicacid
receptor (AMPAR) [23], and gamma aminobutyric acid
receptor GABA(B) antibody encephalitis [24] are recog-
nized. In a few years, the number of onconeural antibodies
described in PNS has increased dramatically. Antibodies to
the components of VGKCs, NMDARs, AMPARs, GABA(B),
mGluR5 receptor, and glycine receptors (GlyRs) can be
identified in patients and are associated with various clinical
presentations, such as limbic encephalitis and complex and
diffuse encephalopathies [23, 25, 26]. These diseases can be
associated with tumors, but some of them are nonparaneo-
plastic, and antibody assays can help with the diagnosis. The
identification of these new antibodies (cell surface antigen
associated) has allowed recognitionof a syndrome with clini-
cal and radiological features indistinguishable from “classic
limbic encephalitis.” The course of the newly identified
syndromes tends to be less severe and it is often possible
t oa c h i e v ec o m p l e t er e c o v e r yw i t hp r o m p ti m m u n o m o d u l a -
tory treatment. The most representative condition is LGI1-
encephalitis, previously known as limbic encephalitis with
VGKC complex antibodies [27, 28].4 Mediators of Inflammation
Table 2: Diagnostic criteria of paraneoplastic limbic encephalitis.
Criteria by Gultekin et al. [13]
Pathological demonstration of limbic encephalitis, or all 4 of the following.
(1) Symptoms of short-term memory loss, seizures, or psychiatric symptoms suggesting involvement of the limbic system
(2) <4yr between the onset of neurological symptoms and the cancer diagnosis
(3) Exclusion of metastasis, infection, metabolic and nutritional deficits, stroke, and side-effects of therapy that may cause limbic
encephalopathy
(4) At least one of the following:
(a) CSF with inflammatory findings
(b) MRI FLAIR or T2 unilateral or bilateral temporal lobe hyperintensities
(c) EEG with epileptic or slow activity focally involving the temporal lobes
Criteria by the Paraneoplastic Neurological Syndrome Euronetwork [14]
All 4 of the following items are met.
(i) Subacute onset (days or up to 12wk) of seizures, short-term memory loss, confusion, and psychiatric symptoms
(ii) Neuropathologic or radiologic evidence (MRI, SPECT, PET) of involvement of the limbic system
(iii) Exclusion of other possible etiologies of limbic dysfunction
(iv) Demonstration of a cancer within 5yr of the diagnosis of neurologic symptoms or the development of classic symptoms of
limbic dysfunction in association with a well-characterized paraneoplastic antibody (Hu, Ma2, CRMP5, amphiphysin, Ri)
These antibodies are directed against two categories
of antigens: (1) intracellular antigens (Hu, Ma2, CRMP5,
a m p h i p h y s i n ,e t c . )a n d( 2 )c e l ls u r f a c ea n t i g e n s( t h eV G K C
complex, NMDAR, AMPARs, GABABRs, mGluR5 receptor,
GlyRs, etc.). Whereas the disorders related to the first cat-
egory of antibodies are associated with cancer (lung, testis,
etc.), prominent brain infiltrates of cytotoxic T cells, and
limitedresponsetotreatment,thedisordersrelatedtothesec-
ond category of antibodies are associated less frequently with
cancer (thymoma, teratoma), seem to be antibody mediated,
and respond significantly better to immunotherapy. These
t w oa n t i b o d i e sh a v ei nc o m m o nt h ea s s o c i a t i o nw i t hi d i o -
pathic or paraneoplastic limbic encephalitis [23, 24]. Seven
out of 15 (47%) patients with limbic encephalitis associated
withGABA(B)receptorantibodieshadanunderlyingtumor,
u s u a l l ya nS C L C[ 24]. In limbic encephalitis associated with
AMPAR antibodies, the frequency of cancer was 64%, with
SCLC being the most common type, followed by thymoma
and breast cancer [23]. These patientshave a better prognosis
than those with antibodies against intracellular proteins [29,
30]. Table 4 summarizes the common antibodies against
onconeural antigens detected in PNS and their potentially
associated tumors.
5. Do Antibodies Play a Pathogenic Role in
Limbic Encephalitis?
A cancer-stimulated immune response that cross-reacts with
neural tissue—onconeural immunity—is considered the
principal pathologic mechanism for PNS [31]. Some cancer
cells express proteins that are normally restricted to the ner-
vous system. For example, when serum from a patient with
limbic encephalitis was incubated with the patient’s cancer
cells and with a rat’s brain tissue, antibody fixation to the
same Ma proteins on both neurons and cancer cells could
be observed [31]. Pathological examination of the nervous
systemshowedlossofneuronsinaffectedareasofthenervous
systemwithinflammatoryinfiltrationbyCD4+Thelpercells
and B cells in the perivascular spaces and cytotoxic CD8+ T
cells in the interstitial spaces [32–34]. Examination of CSF
frequently demonstrates pleocytosis, intrathecal synthesis of
IgG, and oligoclonal bands, supporting an inflammatory or
immune-mediated etiology.
The discovery of paraneoplastic antineuronal antibodies
resultedinthegeneralbeliefthattheseareimmune-mediated
disorders triggered by onconeural antigens expressed by
tumor cells. Despite the clear clinical evidence that many of
thesyndromesdescribedearlierareantibodymediated,there
is lack of direct evidence showing that these antibodies are
pathogenic in PNS. Support for a pathogenic role of antibod-
iescomesfromthefactthatthetargetparaneoplasticantigens
areexpressedbothinthetumorsandintheaffectedregionsof
thenervoussystem.Furthermore,thesizeoftumorsisusually
small and they are heavily infiltrated with inflammatory
cells.Interestingly,spontaneousremissionsofcarcinomamay
occur at the time of neurological presentation [35, 36]. One
studyevenfoundmorelimiteddiseasedistributionandbetter
oncologic outcome in SCLC patients with paraneoplastic
antibodies [37].
There are studies on the effects of the serum or CSF
IgG antibodies on the neuronal function in cultured cells
[22, 23, 38] or on brain slices, but the transfer of clinical
or electrophysiological evidence of disease to experimental
animals by either systemic or intrathecal injection has not
yet been reported, with the exception of mGluR1-Ab in
paraneoplastic cerebellar degeneration [39]a n dr e p o r t so f
GAD-65 or amphiphysin antibodies [40, 41]. In some PNSs,
circumstantial evidence suggests that T-cell-mediated mech-
anisms play a major pathogenic role [42]. It has been sug-
gested that the most important determinant of the under-
lying immunopathogenesis and responsiveness to immuno-
suppression is the antibody type and level of the affected
individual, which may determine the response to treatment
[1, 18, 43].Mediators of Inflammation 5
Table 3: Differential diagnoses of limbic encephalitis.
Infectious disorders
Herpes simplex virus encephalitis
Neurosyphilis
Progressive multifocal leukoencephalopathy
Rabies
Creutzfeldt-Jakob disease
Metabolic disorders
Metabolic encephalopathy (uremic, hepatic, Cushing
syndrome, etc.)
Wernicke-Korsakoff syndrome
Hashimoto’s encephalopathy
Systemic autoimmune disorders
Sj¨ ogren syndrome
Systemic lupus erythematosus
Antiphospholipid syndrome
Malignancies
Lymphoma
Glioma
Gliomatosis cerebri
Degenerative disorders
Alzheimer’s disease
Lewy-body dementia
Frontotemporal dementia
Others
Stroke with posterior cerebral artery involvement
Central nervous system vasculitis
Temporal lobe epilepsy
Nonconvulsive status epilepticus
Transient global amnesia
Acute demyelinating encephalomyelitis
Posterior reversible encephalopathy syndrome
Intoxication (alcohol, lithium, etc.)
Alcohol withdrawal syndrome
Psychiatric disorder
Specifically,strikingdifferenceshavebeenfoundbetween
disorderswithantibodiesagainstintracellularantigensversus
those to neural surface antigens. Disorders with antibodies
to intracellular antigens are considered poorly responsive to
immunotherapy [18, 20]a n dm a yb em e d i a t e db yc y t o t o x i c
Tc e l l s[ 18, 34]. On the other hand, disorders associated with
antibodies against cell surface antigens, such as the VGKC-
complex or NMDAR, often respond well to treatment [20,
44].
Somelaboratoryevidencesupportstheroleofpathogenic
B-cell responses in limbic encephalitis. NMDAR antibodies
from patients have been shown to decrease the numbers of
NMDAR in postsynaptic dendrites of cultured hippocam-
pal neurons. One study suggested that anti-Hu antibodies
inducedapoptosiswhenappliedtoculturesofneuroblastoma
or mesenteric cells [45]. There is also evidence, however,
pointing to that paraneoplastic limbic encephalitis may be
T-cell mediated, as Hu-specific T cells have been found in
the blood and CSF [46], and there are cytotoxic infiltrates of
T cells in the brain and tumor of the patients with anti-Hu
antibodies-associated encephalomyelitis [47].
A pathogenic role could only be proven for those parane-
oplastic antibodies that are directed against easily accessible
antigens located on the cell surface. In these disorders,
indirect lines of evidence support the view that the cellular
immune responses against these antigens are responsible for
the neurological damage [46, 48, 49]. The relative contribu-
tion of the cellular and humoral immunity to the clinical
and pathological manifestations has not been displayed. The
paraneoplastic antibodies may, in these cases, be surrogate
markers for T-cell activation [50]. Elevated CD8/CD3 ratios
in diseases were associated with antibodies to intracellu-
lar antigens and suggested a cytotoxic T-cell-driven path-
omechanism. In diseases with antibodies to surface anti-
gens, this finding supports a B-cell-related pathomechanism,
with evidence of a complement-mediated pathogenesis in
patients with VGKC-complex antibodies. Interestingly, this
immunopathogenic dichotomy parallels other autoimmune
disorders such as polymyositis and dermatomyositis, which
have a predominant T-cell- and antibody-mediated patho-
genesis, respectively [51]. These observations may contribute
to a rational choice in immunotherapies for these disorders
[52]. A totally different mechanism seems at work in para-
neoplastic cerebellar degeneration in Hodgkin’s lymphoma
becausethetargetantigensoftheassociatedanti-Trandanti-
mGluR1 antibodies are not expressed in Hodgkin’s tumor tis-
sue[53].DysregulationoftheimmuneresponseinHodgkin’s
lymphomaandanetiologicroleforviralinfectionshavebeen
postulated in this disorder [53].
Thus far, it is still unclear whether antibody-mediated
PNS, for example, VGKC complex antibody-associated lim-
bic encephalitis, is driven by serum or intrathecal antibodies.
The absolute concentrations of antibodies against a certain
o n c o n e u r a la n t i g e na r eu s u a l l yh i g h e ri ns e r u mt h a ni nt h e
CSF. Moreover, antibodies are not always detectable in the
CSF. Ideally, both serum and CSF samples should be sent
for antibody testing, but their relative utility in followup of
patients is under debate. Intrathecal synthesis of IgG and
oligoclonal bands can help pointing to an immune-mediated
disorder before the results of specific antibodies can be
obtained, but the oligoclonal bands are not always present
at onset or even thereafter, and whether their presence
is evidence for ongoing pathology or merely a secondary
epiphenomenon is not yet clear. The intrathecal synthesis of
antibodies can actually be assessed by the calculation of the
amount of specific antibodies in the CSF relative to the total
CSF IgG and by comparison with similar calculations in the
serum. The ratio represents intrathecal synthesis and is often
higher in some PNS. In favor of a role for systemic rather
than intrathecal antibodies, animal experiments have shown
that certain regions of the brain, that is, the hippocampus6 Mediators of Inflammation
Table 4: The common antibodies detected in PNS and their associated tumors.
Antibodies PNS Associated tumors
Antibodies against intracellular antigens
Anti-Hu sensory neuronopathy, LE, BSE,
encephalomyelitis SCLC
Anti-Yo SCD Gynecological cancer
Anti-Ri Opsoclonus-myoclonus, BSE Breast cancer
Anti-Ma2 BSE, LE Testis cancer, SCLC, breast cancer
Anti-CRMP5 SCD, chorea, myelitis, LE, sensory
neuronopathy, optic neuritis SCLC, thymoma
Anti-amphiphysin SPS, myelitis, SCD, sensory neuronopathy SCLC, breast cancer
Anti-GAD-65 SPS, myelitis SCLC, breast cancer
Anti-SOX-1 LEMS SCLC
Antibodies against cell surface onconeural antigens
Anti-VGCC SPS, LEMS SCLC
Anti-VGKC complex LE SCLC, thymoma
Anti-NMDA receptor LE Teratoma
Anti-AMPA receptor LE SCLC, breast cancer, thymoma
Anti-AQP-4 NMO spectrum disorders SCLC, breast cancer, thymoma
Anti-GABA-B receptor LE SCLC
Anti-CAR Retinopathy SCLC, melanoma, gynecological cancer
Anti-contactin-associated protein 2 Morvan syndrome Thymoma
Anti-AchR/MuSK/RyR/Titin MG Thymoma
AMPA: amino-3-hydroxyl-5-methyl-4-isoxazole-propionate; AQP-4: aquaporin 4; CAR: cancer-associated retinopathy; CRMP5: collapsin response mediator
protein 5; GABA-B: gamma-aminobutyric acid B; GAD-65: glutamic acid decarboxylase 65; LE: limbic encephalitis; LEMS: Lambert-Eaton myasthenic
syndrome; MG: myasthenia gravis; NMDA: N-methyl-D-aspartate; NMO: neuromyelitis optica; SCD: subacute cerebellar degeneration; SCLC: small celll u n g
cancer; SPS: stiff-person syndrome; VGCC: voltage-gated calcium channel; VGKC: voltage-gated potassium channel.
and the hypothalamus, seem to be particularly vulnerable,
anditisnotablethatlimbicencephalitiswithVGKC-complex
(LGI1 and Caspr2) antibodies and anti-NMDAR encephalitis
usually start with symptoms originating from the temporal
lobecortex,eventhoughthetargetantigensarepresentmuch
more widely in the CNS. The former usually affects hip-
pocampus, amygdala, and anterior temporal cortex, whereas
the latter usually affects hippocampus, cerebral cortex, basal
ganglia, and thalamus [54]. Until recently, only 50% of
patients with limbic encephalitis and SCLC were found
antibody positive, usually harboring anti-Hu antibodies or,
less frequently, other onconeural antibodies [29].
Immunopathological analysis of various antibody-asso-
ciated limbic encephalitis may help elucidate the underly-
ing immunopathogenic mechanisms, whereas unfortunately
there has been a lack of laboratory data [52]. Why is limbic
encephalitis reversible in patients with NMDAR antibodies
that are in frequent association with ovarian teratoma [44,
55]? Furthermore, how does one classify those patients with
GAD-65 antibodies that are not paraneoplastic in origin,
who suffer from limbic encephalitis or chronic temporal lobe
epilepsy [20]?
An important issue is that a positive report for any well-
characterizedonconeuralantibodyhastobeassessedaccord-
ing to the clinical setting. All these antibodies, particularly
thoseassociatedwithSCLC,canbefoundinthepatientswith
cancer without PNS [56]. Therefore, one should still rule out
other potential causes of the neurological syndrome that is
being evaluated. Up to 16% of patients with SCLC without
PNS have low titers of Hu antibodies, whereas in the patients
with PNS and Hu antibodies, the titers are substantially
higher [37].
6. Treatments of Limbic Encephalitis
The basic principles of paraneoplastic limbic encephalitis
therapy are resection of the tumor or oncological treatment
[10]. When a patient with tumor is found in association
with a possible paraneoplastic disorder, removal of the
tumor is critical for neurologic improvement or stabilization
of symptoms. Antibodies against onconeural antigens are
sensitive and should prompt an extensive tumor screening
in antibody-positive patients. In the patients with limbic
encephalitis associated with ion channel/receptor antibod-
ies, immunosuppressive or immunomodulatory treatment
is promising to improve the disease. Limbic encephalitides
with antibodies against intracellular onconeural antigens do
notnormallyrespondtoimmunosuppressivetreatment;only
tumortherapymaystabilizethesyndrome.TreatmentofPNS
still remains difficult. Anti-Hu-antibody-positive patients do
not normally respond to immunosuppressive treatment. The
only therapy that stabilizes these patients is perhaps theMediators of Inflammation 7
Table 5: Immunotherapies for limbic encephalitis.
Acute phase of the disease
First-line therapies
High-dose corticosteroids
Intravenous immunoglobulins
Plasma exchange
Second-line therapies
Rituximab
Cyclophosphamide
Maintenance therapy
Steroids
Azathioprine
Mycophenolate
tumor treatment itself [16, 57]. In other PNSs associated
with defined onconeural antibodies, only a few patients
have beneficial effects after treatment [58]. Most patients
with limbic encephalitis and ion channel receptor antibodies
also respond to immunosuppressive or immunomodulatory
treatment [22, 23, 27, 59]. Patients with limbic encephalitis
and antibodies against cell surface antigens such as VGKC or
NMDAR often respond to immunotherapies, such as corti-
costeroids, intravenous immunoglobulin (IVIG), or plasma
exchange. Other therapy regimens that might be of relevance
are rituximab, cyclophosphamide, and azathioprine [60].
In limbic encephalitis patients with intracellular antibodies,
Ma2-positive patients may respond better to immunosup-
pression than patients with anti-Hu or anti-CRMP5 antibod-
ies [61]. Immunotherapies for limbic encephalitis have been
summarized in Table 5.
7. Some Conclusions and More Questions
This field of immune-mediated CNS diseases is exciting but
also challenging. Ideally, antibody testing should be per-
formed using internationally validated procedures so that
the diagnosis can be made and treatments started as soon
as possible in the hope of restoring health, limiting hospi-
talization, and optimizing outcomes. Systematic studies of
the treatments are needed in order to establish the best
practice. Experience with the recently described antibodies,
with exception of those against NMDAR, is still relatively
small. Therefore, their inclusion in one particular group of
the proposed classification must be viewed with caution
untilmorecasesaredescribed.Goodclinical-immunological
correlations are crucial to define the clinical syndrome that
most likely associates with a particular antibody.
The so-far identified antibodies might only be the tip of
the iceberg, with antibodies to other membrane ion channels
or receptors awaiting recognition in future. Even now, the
range of clinical features exhibited by patients with VGKC,
NMDAR, aquaporin (AQP) 4, or GlyR antibodies is wide
andincludesmostaspectsofthenervoussystem.Researchers
in this field must provide good clinical descriptions of the
case series associated with the antibodies they study. This
approach will help clinicians identify the clinical syndromes
and make a rational decision on which antibodies to request.
M o r e o v e r ,m o r ee ff e ct i v em e t h od sa r er e q u i r e df o rt h ed e t e c -
tion of onconeural antibodies [62].
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